Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Improved Pharmacokinetics with BAY 81-8973 Versus Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method: A Randomized Pharmacokinetic Study in Patients with Severe Hemophilia A.
Shah A, Solms A, Garmann D, Katterle Y, Avramova V, Simeonov S, Lissitchkov T. Shah A, et al. Among authors: solms a. Clin Pharmacokinet. 2017 Sep;56(9):1045-1055. doi: 10.1007/s40262-016-0492-2. Clin Pharmacokinet. 2017. PMID: 28005225 Free PMC article. Clinical Trial.
Direct comparison of two extended-half-life recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A.
Shah A, Solms A, Wiegmann S, Ahsman M, Berntorp E, Tiede A, Iorio A, Mancuso ME, Zhivkov T, Lissitchkov T. Shah A, et al. Among authors: solms a. Ann Hematol. 2019 Sep;98(9):2035-2044. doi: 10.1007/s00277-019-03747-2. Epub 2019 Jun 24. Ann Hematol. 2019. PMID: 31236667 Free PMC article. Clinical Trial.
Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the prevention of venous thromboembolism.
Reinecke I, Solms A, Willmann S, Spiro TE, Peters G, Weitz JI, Mueck W, Garmann D, Schmidt S, Zhang L, Fox KAA, Berkowitz SD. Reinecke I, et al. Among authors: solms a. J Thromb Thrombolysis. 2020 Jul;50(1):12-19. doi: 10.1007/s11239-020-02078-8. J Thromb Thrombolysis. 2020. PMID: 32323190 Free PMC article. Clinical Trial.
Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the treatment of venous thromboembolism.
Solms A, Willmann S, Reinecke I, Spiro TE, Peters G, Weitz JI, Mueck W, Garmann D, Schmidt S, Zhang L, Fox KAA, Berkowitz SD. Solms A, et al. J Thromb Thrombolysis. 2020 Jul;50(1):1-11. doi: 10.1007/s11239-020-02073-z. J Thromb Thrombolysis. 2020. PMID: 32323191 Free PMC article. Clinical Trial.
31 results